X4 Pharmaceuticals (XFOR) Preferred Dividend Payments (2017 - 2026)
X4 Pharmaceuticals' (XFOR) quarterly Preferred Dividend Payments came in at $1000.0 in Q2 2026, down 90.0% on a YoY basis from $10000.0 in Q2 2025, and down 92.31% quarter-over-quarter from $13000.0 in Q1 2026.
Powered by 
Analysis
X4 Pharmaceuticals (XFOR) Preferred Dividend Payments (2017 - 2026) Analysis & Trends
X4 Pharmaceuticals (XFOR) has reported Preferred Dividend Payments for 7 consecutive years, with $1000.0 the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Preferred Dividend Payments fell 90.0% year-over-year to $1000.0; the trailing twelve-month figure through Jun 2026 stood at -$15000.0 (up 28.57% YoY), and the FY2025 full-year result was -$13000.0, down 533.33% from the prior year.
- Preferred Dividend Payments fell to $1000.0 in Q2 2026 per XFOR's latest filing, from $13000.0 in the prior quarter.
- Across five years, Preferred Dividend Payments topped out at $2.3 million in Q1 2022 and bottomed at -$45000.0 in Q3 2024.
- Historically, Preferred Dividend Payments has averaged $212666.7 across 4 years, with a median of $7000.0 in 2024.
- The sharpest annual moves came in 2025 and 2026: Preferred Dividend Payments tumbled 212.5% in 2025, then surged 116.67% in 2026.
- Over 4 years, Preferred Dividend Payments stood at $287000.0 in 2022, then sank by 97.21% to $8000.0 in 2024, then sank by 212.5% to -$9000.0 in 2025, then soared by 111.11% to $1000.0 in 2026.
- According to Business Quant data, Preferred Dividend Payments over the past three periods registered $1000.0, $13000.0, and -$9000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Pref Dividends (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | - |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | - |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | - |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | - |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | - |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | - |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | - |
| 10 | X4 Pharmaceuticals | 510.43 Mn | 315.33 Mn | 7.19 Mn | 1,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1,000.00 |
| Mar 31, 2026 | 13,000.00 |
| Dec 31, 2025 | -9,000.00 |
| Sep 30, 2025 | -20,000.00 |
| Jun 30, 2025 | 10,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2024 | 8,000.00 |
| Sep 30, 2024 | -45,000.00 |
| Jun 30, 2024 | 6,000.00 |
| Mar 31, 2024 | 36,000.00 |
| Sep 30, 2022 | 287,000.00 |
| Mar 31, 2022 | 2.26 Mn |
| Mar 31, 2019 | 592,000.00 |
| Dec 31, 2018 | 756,000.00 |
| Sep 30, 2018 | 756,000.00 |
| Jun 30, 2018 | 748,000.00 |
| Mar 31, 2018 | 22,000.00 |
| Dec 31, 2017 | 2.96 Mn |
| Sep 30, 2017 | 16,000.00 |
| Jun 30, 2017 | 13,000.00 |